Annovis Bio (ANVS) Q3 2025 earnings summary

Executive summary

• Focused on late-stage clinical development of buntanetap for Alzheimer's and Parkinson's diseases, with recent completion of key Phase 2/3 and Phase 3 trials and ongoing pivotal Phase 3 AD trial initiated in February 2025.

• Achieved full activation of all 84 clinical sites for pivotal Phase 3 Alzheimer's study, with strong enrollment and first patients completing 6-month treatment milestone.

• Published new pharmacokinetic data validating the novel crystalline form of buntanetap and secured global IP protection through 2046.

• Announced significant biomarker reductions in neuroinflammation and neurodegeneration in Phase 2/3 AD trial, supporting disease-modifying potential.

• No product revenue to date; operations funded primarily through equity offerings and warrant issuances.

Financial highlights

• Net loss of $7.3 million for Q3 2025, an improvement from $12.6 million in Q3 2024; net loss of $19.0 million for the nine months ended September 30, 2025, compared to $18.7 million for the same period in 2024.

• Research and development expenses rose to $6.3 million in Q3 2025, mainly due to increased costs for the AD 6-month trial; general and administrative expenses decreased to $1.1 million.

• Cash and cash equivalents were $15.3 million as of September 30, 2025, up from $10.6 million at year-end 2024, excluding $9.4 million in October offerings.

• Net loss per share improved to $0.37 for Q3 2025 from $0.97 in Q3 2024.

• Operating cash burn for the nine months ended September 30, 2025 was $16.7 million.

Outlook and guidance

• Current cash is expected to fund operations until Q3 2026, but additional capital will be required to support ongoing and future clinical development.

• Progress toward symptomatic readout and NDA submission is on track, with all clinical and operational elements aligned.

• Management plans to seek further funding through equity, debt, or other alternatives; failure to secure capital may require scaling back or ceasing operations.